December 4, 2024 - 04:41

Salesforce (CRM) and Okta (OKTA) are scheduled to release their earnings reports after the market closes, shedding light on the current state of the software industry. Marvell Technology (MRVL) will also unveil its financial results, adding to the day's significant announcements. As these companies prepare to disclose their performance, the stock markets are experiencing a period of stability, hovering around the flat line following record highs for both the S&P 500 and Nasdaq Composite.
With the impending second term of President-elect Donald Trump, investors are closely analyzing the potential effects of his tariff policies on various sectors. The market sentiment is mixed, with traders keeping a watchful eye on how these earnings reports may influence stock prices.
In addition to the earnings announcements, several key guests will be featured throughout the day, including investment strategists and industry leaders from various companies. Their insights may provide valuable perspectives on market trends and economic forecasts as investors navigate this pivotal time.
November 13, 2026 - 18:59
Egypt-UAE Banking Relations Under Pressure from US SanctionsThe banking connections between Egypt and the UAE are facing significant strain due to escalating threats of US sanctions. Recent developments indicate that the US government is closely monitoring...
November 13, 2026 - 07:24
Burry Observes Strong Demand for NVDA Stock Amid ConcernsMichael Burry noted a `mechanical bid` that surged at the opening of trading on Thursday, suggesting that fund flows and established investment rules were overpowering sellers. This phenomenon...
November 12, 2026 - 21:40
Codexis Reports Third Quarter LossCodexis announced its financial results for the third quarter, revealing a loss of 8 cents per share. The Redwood City, California-based biotechnology firm faced challenges during this period,...
November 12, 2026 - 01:35
Is Now the Right Time to Invest in Halozyme Stock?Investors are closely watching Halozyme Therapeutics as potential opportunities arise in the biotech sector. With a recent surge in interest, many are wondering if now is the time to buy into the...